Apollo Hospitals Analyst Review 2027: Why Three Brokers Raised Targets Above ₹10,000 After a 32% Profit Rise
- November 17, 2026
- Posted by: Chaitanya Auti
- Category: Market
Apollo Hospitals Enterprise Stock Snapshot (16 Nov 2026 close)
- Current Market Price (CMP): ₹8,771
- 52-Week High / Low: ₹9,070.50 / ₹6,696.50
- Market Capitalisation: ₹1,25,901 crore
- P/E Ratio vs Industry P/E: 53.9 vs 62.5
- Latest Quarter (Q2 FY27) Revenue: ₹7,615 crore (consolidated)
- Latest Quarter (Q2 FY27) Net Profit: ₹630 crore (consolidated)
Quick Answer: The Apollo Hospitals analyst review 2027 is firmly positive. After Q2 FY27, when revenue rose 23% to ₹7,615 crore and profit rose 32% to ₹630 crore, Prabhudas Lilladher raised its target to ₹10,500, Motilal Oswal set ₹10,400 and Choice kept ₹9,600. ICICI Direct’s August target of ₹10,170 also sits above the market. At ₹8,771 those calls imply about 9% to 20% upside. The debate is no longer about growth but about how fast margins can rise while the company pays for new beds, staff and the HealthCo restructuring.
The Apollo Hospitals analyst review 2027 is shaped by a quarter in which almost every segment moved the right way. For readers tracking the Apollo Hospitals share price target 2027, the September 2026 quarter delivered consolidated revenue of ₹7,615 crore, up 23%, EBITDA of ₹1,191 crore, up 29%, and profit after tax of ₹630 crore, up 32%. The digital health business also reached cash breakeven for the first time.
Apollo Hospitals Enterprise closed at ₹8,771 on 16 November 2026, about 3% below its 52-week high of ₹9,070.50 and 31% above its low of ₹6,696.50. It is one of the healthcare names in the Nifty 50. This Apollo Hospitals analyst review 2027 covers the targets, the results, how the group earns and the factors behind the Apollo Hospitals stock outlook 2027.
Click Here – Get Free Investment Predictions
What Analysts Say in the Apollo Hospitals Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| Prabhudas Lilladher (PL Capital) | Buy | ₹10,500 | November 2026 |
| Motilal Oswal Financial Services | Buy | ₹10,400 | November 2026 |
| ICICI Direct (ICICI Securities) | Buy | ₹10,170 | August 2026 |
| Choice Institutional Equities | Add | ₹9,600 | November 2026 |
Three of the four calls came within two days of the 4 November results. Prabhudas Lilladher lifted its target to ₹10,500 from ₹10,000, noting that Apollo HealthCo was scaling and that the digital business had reached cash breakeven. Motilal Oswal said the profit beat was led by hospitals and HealthCo, with volume-driven hospital growth and leaner digital spending keeping earnings on an upward path. Choice kept its ₹9,600 target with an Add rating, valuing the company on an average of FY28 and FY29 sum-of-the-parts estimates.
In this Apollo Hospitals analyst review 2027, every verified brokerage target is above the price. The difference between ₹9,600 and ₹10,500 is mostly about how quickly margins can expand once current investments start paying back.
Q2 FY27 Results in the Apollo Hospitals Analyst Review 2027
| Metric | Q2 FY27 | Change vs Q2 FY26 |
|---|---|---|
| Consolidated Revenue | ₹7,615 crore | +23% |
| Consolidated EBITDA | ₹1,191 crore | +29% |
| Profit After Tax | ₹630 crore | +32% |
| EBITDA Margin (approx.) | 15.6% | Higher |
The pattern of profit rising faster than revenue is what investors in the Apollo Hospitals analyst review 2027 wanted to see. EBITDA grew 29% against revenue growth of 23%, which means each rupee of sales is earning more. The hospital business drove most of it through higher patient volumes, while HealthCo, which houses the pharmacy distribution and digital platforms, narrowed losses.
For the Apollo Hospitals analyst review 2027, the sequential trend matters too. Profit has now risen quarter after quarter through FY26 and into FY27, which is why brokers moved quickly to raise their estimates.
How Apollo Hospitals Makes Money
- Healthcare services: a large network of hospitals across India, earning from inpatient stays, surgeries, diagnostics and outpatient visits.
- Apollo HealthCo: offline pharmacy distribution, the Apollo 24/7 digital platform and online pharmacy.
- Apollo Health and Lifestyle (AHLL): clinics, diagnostics centres, cradle and birthing units, and day-care centres.
- Insurance: a newer insurance business that is still loss-making at the EBITDA level.
Hospitals carry the highest margins and drive most of the valuation. HealthCo brings scale and customer reach but thinner margins. That is why the Apollo Hospitals analyst review 2027 calls are built on sum-of-the-parts methods, valuing each segment separately.
Growth Triggers in the Apollo Hospitals Analyst Review 2027
- Bed additions: new hospitals and expansions under way should add capacity through FY27 and FY28, though new units usually lose money for a year or two.
- HealthCo restructuring: the planned transaction and demerger around pharmacy and digital health could create a separately valued, listed entity.
- Digital breakeven: cash breakeven in Q2 FY27 removes a drag that had weighed on group profit.
- Insurance breakeven: ICICI Direct noted in August that management expected the insurance business to break even by the end of Q3 FY27.
- Healthcare demand: rising insurance cover and lifestyle disease prevalence keep patient volumes growing.
The stock also moves with the broader BSE Healthcare index, which has been one of the steadier sectors over the past year.
Key Risks in the Apollo Hospitals Analyst Review 2027
- Margin pressure in FY27: Prabhudas Lilladher flagged manpower investment, employee bonuses and one-time integration costs as near-term weights.
- Drug price caps: price caps on oncology medicines could squeeze pharmacy and distribution margins.
- Insurance losses: the insurance business remains EBITDA negative.
- New hospital ramp-up: fresh capacity takes time to fill and can dilute group margins.
- Valuation: a P/E of about 54 is high in absolute terms, though below the industry figure of about 62.
Compare Apollo Hospitals With Hospital and Healthcare Peers on the Univest Screener
Apollo Hospitals Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (16 Nov 2026 close) | ₹8,771 |
| 52-Week High / Low | ₹9,070.50 / ₹6,696.50 |
| Market Capitalisation | ₹1,25,901 crore |
| P/E (TTM) vs Industry | 53.9 vs 62.5 |
| Price to Book | 11.87 |
| Book Value per Share | ₹737.51 |
| Return on Equity | 21.14% |
| Debt to Equity | 0.77 |
| FY26 Revenue / Net Profit | ₹25,420 crore / ₹2,003 crore |
In the Apollo Hospitals analyst review 2027, a return on equity above 21% with debt to equity under 1 is a healthy combination for a capital-heavy hospital chain. Operating cash flow of ₹2,856 crore in FY26 covered capex of ₹1,962 crore comfortably.
Shareholding Trend
| Holder | Sep 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Promoters | 28.02% | 28.02% | 28.02% | 28.02% |
| Foreign Institutions (FII) | 44.20% | 42.62% | 41.50% | 43.18% |
| Domestic Institutions (DII) | 21.12% | 22.76% | 23.72% | 22.07% |
| Public | 6.66% | 6.60% | 6.77% | 6.72% |
In the Apollo Hospitals analyst review 2027 period, foreign investors owned more of Apollo than the founding Reddy family. FII holding dipped through June 2026 and then rebounded to 43.18% in September, while domestic funds took some profit. The promoter stake, led by PCR Investments at 18.93%, has stayed flat at 28.02%.
What to Watch After the Apollo Hospitals Analyst Review 2027
- HealthCo transaction: timing and structure of the pharmacy and digital health demerger.
- Insurance breakeven: whether it arrives by the end of Q3 FY27 as guided.
- Hospital occupancy: volume growth in mature hospitals and ramp-up at new ones.
- Oncology price caps: any measurable impact on pharmacy margins.
- Target changes: fresh moves in the Apollo Hospitals share price target 2027 range of ₹9,600 to ₹10,500.
Final Word on the Apollo Hospitals Analyst Review 2027
The Apollo Hospitals analyst review 2027 shows a company where growth is broad and profit is rising faster than sales. A 32% rise in quarterly profit, digital cash breakeven and steady hospital volumes explain why three brokerages lifted or kept targets above ₹9,600 within days of results.
What could slow the Apollo Hospitals stock outlook 2027 is cost. Staff investment, integration expenses, drug price caps and the insurance arm all weigh on margins this year. The stock already trades near its high, so delivery on margins in FY28 is what the targets depend on. Univest does not give a buy or sell call on the stock.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Apollo Hospitals analyst review 2027 show?
It shows four positive brokerage calls, three of them published after Q2 FY27 results on 4 November 2026. Revenue rose 23% to ₹7,615 crore and profit after tax rose 32% to ₹630 crore. The digital health business also reached cash breakeven.
What is the Apollo Hospitals share price target 2027 from brokerages?
Prabhudas Lilladher has ₹10,500, Motilal Oswal ₹10,400 and Choice ₹9,600, all from November 2026. ICICI Direct’s ₹10,170 target dates from August 2026. Against the ₹8,771 close on 16 November 2026, that implies roughly 9% to 20% upside.
Why did profit grow faster than revenue in the Apollo Hospitals analyst review 2027 quarter?
EBITDA grew 29% to ₹1,191 crore against revenue growth of 23%, because hospital volumes rose and digital spending was trimmed. HealthCo narrowed its losses and the digital business turned cash positive. Profit after tax therefore rose 32%.
What is Apollo HealthCo in the Apollo Hospitals analyst review 2027?
Apollo HealthCo is the arm that runs offline pharmacy distribution and the Apollo 24/7 digital platform. Brokers value it separately from the hospital business in their sum-of-the-parts models. A planned transaction and demerger could make it a separately listed entity.
Is Apollo Hospitals expensive compared with its industry?
The stock trades at a P/E of about 53.9 against an industry P/E of about 62.5. Its return on equity is 21.14% and price to book is 11.87. The premium in absolute terms reflects steady earnings growth and strong cash generation.
What risks does the Apollo Hospitals analyst review 2027 highlight?
Prabhudas Lilladher flagged manpower investment, bonuses and one-time integration costs as pressures on FY27 margins. Price caps on oncology drugs could hurt pharmacy margins, and the insurance business is still EBITDA negative. New hospitals also take one to two years to reach profitability.
What should investors track after the Apollo Hospitals analyst review 2027?
Watch the HealthCo restructuring, insurance breakeven by the end of Q3 FY27 and hospital occupancy trends. Any impact from oncology price caps will show up in pharmacy margins. Target revisions within the ₹9,600 to ₹10,500 band will also signal how brokers view progress.